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Abstract
Background: The incidence of breast cancer in young women (age < 35) is low. The biology of
the disease in this age group is poorly understood, and there are conflicting data regarding the
prognosis for these women compared to older patients.
Methods: We retrospectively analyzed 2040 consecutive primary invasive breast cancer patients
who underwent surgical procedures at our institution between 1990 and 1999. The younger age
group was defined as patients aged <35 years at the time of diagnosis. The clinicopathological
characteristics and treatment outcomes were compared between younger and older age groups.
Results: A total of 256 (12.5%) patients were aged <35. There was a significantly higher incidence
of nuclear grade 3 and medullary histological-type tumors in younger patients compared to older
patients. Axillary lymph node status, T stage, histological grade, c-erbB2 expression and estrogen
receptor status did not differ significantly between the two age groups. Younger patients had a
greater probability of recurrence and death at all time periods. Although there was no significant
difference in disease-free survival between the two age groups in lymph node-negative patients, the
younger group showed worse prognosis among lymph node-positive patients (p < 0.001). In
multivariate analysis, young age remained a significant predictor of recurrence (p = 0.010).
Conclusion: Young age (<35) is an independent risk factor for relapse in operable breast cancer
patients.
Background
Breast cancer is relatively rare in women less than 35 years
of age, with this group accounting for less than 4% of the
total number of breast cancer cases diagnosed in Western
countries [1,2]. Despite the disease being relatively
uncommon, it has a severe negative effect on the patients
and their families.
It remains controversial whether young age at diagnosis is
an adverse prognostic factor in primary breast cancer.
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While some studies have found that younger patients
have worse clinical outcomes than older patients [3-7],
others report younger patients have a more favorable
prognosis, or that there is no relationship between out-
come and age [8-10]. Various explanations have been
given for these conflicting results, including small num-
bers of patients comprising the study population, differ-
ences in patient selection criteria and differences in the
age groupings used in the analyses. Moreover, it has long
been debated whether breast cancer diagnosed at a young
age is a clinically and etiologically distinct disease from
breast cancer diagnosed later in life. Some researchers
reported that tumors in younger women were of higher
grade, higher proliferation fraction, had more vascular
invasion, and expressed fewer estrogen and progesterone
receptors compared to tumors in older women [11-14]. It
is important for clinicians to clarify the existing contro-
versy as to whether aggressive treatment for young women
with breast cancer is justified.
Breast cancer is the most frequent cancer in Korean
women and its incidence is increasing [15]. Breast cancer
in young Korean women is a serious problem, with the
proportion of young age-onset breast cancer much higher
than in western countries. According to the 2002 annual
report of the Korean central cancer registry, breast cancers
that developed before the age of 35 comprised 9.5% of all
breast cancers [16].
The aim of the present study was to retrospectively inves-
tigate clinicopathological characteristics and prognosis in
a large, ethnically homogeneous group of young breast
cancer patients (less than 35 years old) treated with the
same strategy at a single institution.
Methods
A retrospective review was performed of the medical
records of all consecutive primary invasive breast cancer
patients (not including phyllodes tumor) undergoing cur-
ative surgery in the Department of Surgery, Seoul National
University Hospital between January 1990 and December
1999. Patients with distant metastasis detected at the time
of surgery or within 4 months of surgery were excluded.
Those patients whose surgical margins were positive for
malignancy were also excluded. Patients' records were
reviewed for the following: age of onset, family history of
breast cancer in 1st or 2nd degree relatives, histological
type of cancer, tumor size in pathology reviews, axillary
lymph node status, histological grade (HG: Scarff-Bloom-
Richardson classification), nuclear grade (NG: Black's
nuclear grade), type of surgical procedure and adjuvant
therapy administered. Disease was staged according to the
American Joint Committee of Cancer (AJCC) system [17].
The 'younger' group was defined as patients less than 35
years old at the time of breast cancer diagnosis. Expression
of immunohistochemical tumor markers such as estrogen
receptor (ER), progesterone receptor (PR) and c-erbB2
were determined in over 70% of cases. The expression was
determined in assays performed immediately after surgery
for each case. The primary antibodies for ER (DAKO,
Glostrup, Denmark), PR (DAKO, Glostrup, Denmark)
and c-erbB2 (Novocastra, Newcastle, UK) have been pre-
viously characterized. A cut-off value of 10% or more pos-
itively stained cells out of total cells in ten high-power
fields was used in the classification of ER, PR and c-erbB2
expression levels.
Statistical analysis
The χ2 test (Pearson statistic) was used to determine the
differences in clinicopathological features between the
two groups of patients. The follow-up duration was calcu-
lated from the date of diagnosis until the date of death or
last contact. The disease-free survival was the time
between diagnosis and confirmation of disease recur-
rence. The overall survival was the time between diagnosis
and death as a result of any cause, regardless of recurrence
events. Survival estimates were computed using the Kap-
lan-Meier method [18] and the differences between sur-
vival times were assessed by means of the log rank test
[19]. Multivariate analyses were carried out using Cox's
proportional hazards model [20]. All statistical analyses
were carried out using the SPSS (version 10.0) software
package (Chicago, IL, USA).
Results
A total of 2040 patients were eligible for this study, of
which 256 (12.5%) were aged <35 at the time of diagno-
sis. The median follow-up was 74 months. Histology
showed the incidence of medullary carcinoma was signif-
icantly higher than ductal carcinoma in the younger group
(p = 0.018). There was a significantly higher incidence of
nuclear grade 3 in the younger group than in the older
group (p = 0.015). Axillary lymph node status, the most
prominent prognostic factor in breast cancer, was not sig-
nificantly different between the two age groups. Also, nei-
ther the family history of breast cancer in 1st or 2nd degree
relatives, T stage, histological grade, c-erbB2 expression,
nor ER or PR status were different between the two groups
(Table 1). Frequencies of ER and PR positivity were low,
and frequency of c-erbB2 positivity was high, in both age
groups compared to frequencies reported in western pop-
ulations and other Asian studies [21-23].
The proportion of breast-conserving surgery compared to
mastectomy was similar in both groups. Axillary lymph
node dissection, at least to the first Berg level [24], was
performed in 250 (97.7%) younger patients and 1735
(97.3%) older patients. No sentinel lymph node proce-
dure was performed. Adjuvant radiation therapy was
administered to patients who underwent breast-conserv-BMC Cancer 2004, 4:82 http://www.biomedcentral.com/1471-2407/4/82
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ing surgery and after mastectomy in patients who had four
or more positive lymph nodes or a tumor >5 cm in diam-
eter. Adjuvant chemotherapy was administered to 68.0%
of younger and 58.7% of older patients. The most com-
mon chemotherapy regimen was a combination of cyclo-
phosphamide + methotrexate + 5-FU (CMF) for 6 cycles
or anthracycline containing regimen (AC). In terms of
hormone therapy, tamoxifen was used for as long as 5
years after completion of surgery and adjuvant therapy.
We classified a patient as tamoxifen treatment group if she
got tamoxifen through more than a year before recur-
rence. The proportion of tamoxifen treated patients was
significantly lower in young age group. Neither the type of
surgery nor the postoperative adjuvant choemotherapy
was significantly different between the two age groups
(Table 2).
Younger patients had a worse disease free survival (greater
probability of recurrence) at all time periods (Fig 1A; p <
0.001). At 5 years, the actuarial recurrence rate for patients
<35 years old was 30.4% as compared with 18.7% for
older patients. This difference persisted at 10 years, at
which time the actuarial recurrence rates were 40.1% and
28.6%, respectively. Overall survival among younger
patients was significantly worse than for older patients
(Fig 1B; p = 0.002). The 5-year survival rate was 80.0% for
patients aged <35 years as compared with 88.5% for older
patients. Stratified analysis according to axillary lymph
node status was performed for disease-free survival. In
lymph node-negative patients there was no significant dif-
ference in disease-free survival between the two age
groups (Fig 2A; p = 0.223). However, in lymph node-pos-
itive patients, disease-free survival was significantly worse
in younger patients (Fig 2B; p < 0.001).
In multivariate analysis, young age (<35 years) remained
a significant predictor of recurrence when entered into a
model containing all potential demographic, pathologic
and immunohistochemical variables (Table 3. Hazard
Ratio (HR), 1.7; 95% confidence interval, 1.1–2.6; p =
0.010). However, young age was not a significant inde-
pendent predictor of overall survival in the same Cox
model (table not shown. HR, 1.4; p = 0.242). Because hor-
mone therapy was done more frequently in older patients
than young age group (Table 2.), we made another multi-
variate model involving hormone therapy in patients with
ER positive and/or PR positive cancer to address the effect
of hormone therapy on the prognostic significance of
young age. In this analysis, young age was still an inde-
pendent significant prognostic factor while hormone ther-
apy showed borderline significance (Table 4.).
Discussion
Our results showed that operable young breast cancer
patients (<35 years old) have a worse prognosis than older
Table 1: Clinicopathological characteristics of younger (<35) and 
older age groups
Characteristics Age <35 (%) 
(n = 256)
Age ≥ 35 (%) 
(n = 1784)
P value
Age
20–25 9 (3.5)
26–30 56 (21.9)
31–35 191 (74.6)
36–40 318 (17.8)
41–50 791 (44.3)
51–60 474 (26.6)
60–70 165 (9.2)
71- 36 (2.0)
Family historya 22 (8.7) 135 (7.6) 0.511
Histology
Ductal 238 (93.0) 1624 (91.0)
Lobular 2 (0.8) 30 (1.7)
Medullary 10 (3.9) 29 (1.6) 0.018
others 6 (2.3) 101 (5.7)
T stage
T1 99 (38.7) 770 (43.2)
T2 129 (50.4) 855 (47.9)
T3–4 28 (10.9) 159 (8.9) 0.126
Lymph node metastasis
Negative 138 (53.9) 1063 (59.6)
Positive 118 (46.1) 721 (40.4) 0.084
Histological grade
1–2 78 (58.6) 525 (60.0)
3 55 (41.4) 350 (40.0) 0.767
Nuclear grade
1–2 113 (52.6) 901 (61.3)
3 102 (47.4) 570 (38.7) 0.015
ER
Positive 97 (47.1) 907 (51.8)
Negative 109 (52.9) 843 (48.2) 0.198
PR
Positive 73 (36.7) 708 (43.5)
Negative 126 (63.3) 921 (56.5) 0.068
c-erbB2
Negative 94 (52.8) 647 (46.4)
Positive 84 (47.2) 748 (53.6) 0.106
aPatients who have 1st or 2nd degree relatives with breast cancer
Table 2: Treatment characteristics
Characteristics Age <35 (%) Age ≥ 35 (%) P value
Surgery
Mastectomy 211 (82.4) 1482 (83.1) 0.796
Conservation 45 (17.6) 302 (16.9)
Chemotherapy
Lymph node (-) 65/138 (47.1) 421/1063 
(39.6)
0.281
Lymph node (+) 109/118 
(92.4)
627/721 (87.0) 0.674
Radiation therapy 73 (28.5) 462 (25.9) 0.373
Hormone therapy 54 (21.1) 492 (27.6) 0.028BMC Cancer 2004, 4:82 http://www.biomedcentral.com/1471-2407/4/82
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patients in terms of both overall survival and recurrence.
The difference in disease-free survival was clear in patients
with axillary lymph node metastasis, but was not
observed in lymph node-negative patients. Even after
controlling for differences in distribution of potential
prognostic factors, young age remained a significant pre-
dictor of recurrence.
The present findings support previous reports showing
that women diagnosed with breast cancer at a younger age
have a poorer prognosis compared with their older coun-
terparts [3-7]. However, those reports suffered from
limitations including a small younger patient sample size,
a study period spanning too many years during which
treatments changed, lack of information about patholog-
ical and protein markers, and a heterogeneous case popu-
lation in terms of ethnicity and treatment strategy.
To our knowledge, the present study is the largest to
directly compare the prognosis of younger (<35) breast
cancer patients with that of their older counterparts.
Moreover, the data in this study were generated from
patients of the same ethnicity undergoing treatment at a
single institution under the same contemporary strategy
of surgery and adjuvant therapy over a relatively short
time period (10 years). In addition, this study included a
multivariate analysis of the difference in distribution of
potential prognostic markers between the two age groups.
The biomarker results in the present study are different to
those reported for other populations, including ethni-
cally-related Asian patients. In a study of 1052 Chinese
breast cancer patients in Hong Kong, 53% and 61.6% of
pre- and postmenopausal women were ER-positive,
respectively, and 51.5% and 46.2% were PR-positive,
(A) Disease-free survival curves for women <35 vs. ≥ 35 years old Figure 1
(A) Disease-free survival curves for women <35 vs. ≥ 35 years old. Patients younger than 35 had significantly worse outcomes 
than their older counterparts (p < 0.001). (B) Overall survival curves showing patients younger than 35 had significantly worse 
outcomes than their older counterparts (p = 0.002).
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respectively [21]. Those figures are higher than the figures
reported in the present study. A recent study of Japanese
patients showed 62.2% were ER-positive and only 17.2%
were c-erbB2-positive [22]. Merchant et al. found c-erbB2
expression in 30% and 24% of British and Japanese breast
cancer patients, respectively [23]. In contrast, Choi et al.
reported significant differences in c-erbB2 expression
(A) Disease-free survival curves in axillary lymph node-negative patients showing no significant difference between the two age  groups (p = 0.223) Figure 2
(A) Disease-free survival curves in axillary lymph node-negative patients showing no significant difference between the two age 
groups (p = 0.223). (B) Disease-free survival curves in axillary lymph node-positive patients showing patients younger than 35 
had significantly worse outcomes than their older counterparts (p < 0.001).
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Table 3: Multivariate analysis for predictors of recurrence based 
on the Cox proportional hazards regression model
Variables HR 95% Confidence interval p
Age <35 years 1.7 1.14–2.61 0.010
Tumor size ≥ 2 cm 2.0 1.30–3.07 0.002
Lymph node-positive 3.8 2.64–5.67 <0.001
Nuclear grade 3 1.4 0.90–2.39 0.124
Histological grade 3 0.9 0.54–1.49 0.675
ER 1.1 0.77–1.63 0.549
PR 2.1 1.41–3.19 0.001
c-erbB2 1.4 1.04–2.05 0.030
Table 4: Multivariate analysis for predictors of recurrence 
involving hormone therapy in ER(+) and/or PR(+) patients
Variables HR 95% Confidence interval p
Age <35 years 2.1 1.14–4.20 0.018
Tumor size ≥ 2 cm 2.2 1.39–3.62 0.001
Lymph node-positive 3.3 1.81–6.14 <0.001
Nuclear grade 3 1.0 0.45–2.31 0.961
Histological grade 3 1.2 0.55–2.85 0.576
Hormone therapy (yes) 1.6 0.93–2.77 0.086
c-erbB2 1.4 0.81–2.42 0.228BMC Cancer 2004, 4:82 http://www.biomedcentral.com/1471-2407/4/82
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between Korean and white patients (47.5 vs. 15.8%,
respectively) using immunohistochemistry and fluores-
cence in situ hybridization (FISH) techniques. These data
suggest c-erbB2 expression may be related to race [25].
Although not a major focus of this study, we found PR and
c-erbB2 expression were significant independent predic-
tors of disease recurrence. Currently, the role of PR status
as a prognostic factor is not clear, with some evidence to
suggest it is useful [26,27] and other evidence to the con-
trary [28]. As for c-erbB2, its prognostic importance is also
controversial. A large number of studies have been pub-
lished, some reporting positive results and others report-
ing negative results [29-31]. The prognostic significance of
PR and c-erbB2 in this data set can be investigated further
as an independent analysis later.
The St. Gallen Consensus Conferences in 1998 and 2001
concluded that age under 35 was a high risk factor for
relapse in node-negative breast cancer patients [32,33].
Kroman et al. [34] reported that young women with low-
risk breast carcinoma who did not receive adjuvant treat-
ment had a significantly increased risk of death from the
disease. Furthermore, Fowble et al. [4] reported that
young women with early stage breast cancer, especially
those with lymph node-negative disease, had a relatively
worse prognosis than older counterpart. In the present
study, although no significant difference was observed
between the two age groups in lymph node-negative
patients, the pattern of survival curves implied younger
patients may have a worse prognosis. It may be that a
study with a larger case size and a longer follow-up dura-
tion would provide enough statistical power to show a sig-
nificant difference in prognosis for node-negative
patients.
It has been suggested that younger women with breast
cancer have a poorer prognosis because they present with
later stage disease due to either physician or patient delay
in diagnosis. However, in this study, no significant differ-
ence was found between the two age groups in terms of
tumor size or lymph node status. Moreover, multivariate
analysis indicated that young age is an independent nega-
tive prognostic factor. This issue of delayed diagnosis is
not conclusive now and should be elucidated further in
subsequent studies.
One possible limitation of this study is that the control
group was heterogeneous and contained a mixture of pre-
menopausal and postmenopausal patients. Adami et al.
showed complex pattern of survival as a function of age at
diagnosis of breast cancer [12]. However, as shown in
Table 4, young age remained an independent prognostic
factor in multivariate analysis even after patients aged
over 50 years were excluded from the control group (p =
0.008). Although we did not have full information on
each patient's menopausal status at the time of diagnosis,
this result suggests that patients under 35 years have even
worse prognosis than relatively "less young age" premen-
opausal patients.
Up to 15–30% of women aged less than 35 years diag-
nosed with breast cancer are likely to have germ-line
BRCA1 or BRCA2 mutations [35,36]. Although we did not
investigate BRCA gene mutations in all patients in the
present study, we performed BRCA1 and BRCA2 gene
mutation scanning in 22 patients who had two or more
breast cancer patients in their 1st degree relatives. We
found four BRCA2 and one BRCA1 mutations that are
thought to be disease-causing (data not shown). Only one
of these 5 patients was less than 35 years old at the time
of cancer development. It is known that young breast can-
cer patients are more likely to have an inherited form of
the disease [37]. However, the current study showed there
was no significant difference in the family history of breast
cancer between the two age groups. In the recent report by
Choi et al. the prevalence of BRCA1 and BRCA2 muta-
tions in Korean women with breast cancer at a young age
(<40) was as high as western population. However, most
of the BRCA-associated patients had no family history of
breast and/or ovarian cancer. That is, the penetrance
appears to be low. They suggested that there may be differ-
ent genetic and etiologic factors affecting transmission
and penetrance of the BRCA genes in Korean patients with
breast cancer diagnosed at a young age [38].
Although most current breast cancer investigators agree
that young age is an adverse prognostic factor for breast
cancer, there have been few studies designed to elucidate
the molecular or genetic differences associated with young
age breast cancer. Recent CGH (Comparative Genomic
Hybridization) analysis suggested that alterations in spe-
cific regions on chromosomes might be responsible for
the poor outcome of early onset breast cancer [39]. Future
research must be focused on this area in order to confirm
the characteristics of young age-onset breast cancer at the
molecular level.
Conclusions
These results show that operable young breast cancer
patients (<35 years old) have a worse prognosis than older
patients in terms of both overall survival and recurrence.
Even after controlling for differences in distribution of
potential prognostic factors, young age is an independent
predictor of recurrence. The underlying biology of young
age breast cancer needs to be elucidated and development
of tailored treatment for this patient population is crucial.BMC Cancer 2004, 4:82 http://www.biomedcentral.com/1471-2407/4/82
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